NCT02228369 - Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

November 5, 2014

Primary Completion Date

August 19, 2017

Study Completion Date

October 28, 2020

Conditions

EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

Interventions

DRUG

AZD3759

Starting dose 50 mg, administered twice daily. If tolerated subsequent cohorts will test increasing doses of AZD3759, until a maximum tolerated dose or an effective dose is defined

DRUG

AZD9291

AZD9291 160mg once daily

Trial Locations (10)

2050

Research Site, Camperdown

3084

Research Site, Heidelberg

10002

Research Site, Taipei

13620

Research Site, Seongnam-si

90048

Research Site, Los Angeles

90404

Research Site, Santa Monica

03080

Research Site, Seoul

03722

Research Site, Seoul

05505

Research Site, Seoul

135-710

Research Site, Seoul